Advanced Cell Diagnostics (ACD), a Bio-Techne
spatial biology brand, achieves technical breakthrough enabling
protease-free, same-slide detection of protein and RNA biomarkers
using industry-leading RNAscope™ technology.
MINNEAPOLIS, Jan. 29,
2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:
TECH) today announced that Advanced Cell Diagnostics (ACD), a
Bio-Techne spatial biology brand, has set a new standard with the
development of a next-generation, protease-free RNAscope spatial
multiomics workflow. Optimized for same-slide detection of protein
and RNA biomarkers with unparalleled sensitivity and tissue
morphology, the newly developed RNAscope spatial multiomics
workflow is compatible with both manual and automated assays. ACD's
novel protease-free RNAscope workflow is incorporated in
Bio-Techne's recently announced best-in-class multiomics
application on Lunaphore's COMET platform.
Simultaneous imaging of both RNA and protein biomarkers on the
same tissue section will provide an unprecedented single-cell view
of disease pathology and therapeutic response. ACD's new innovation
marks a significant improvement over existing spatial technologies
which are designed for the detection of either RNA or protein, not
both, and typically lead to the degradation of the alternate
biomarker type.
By eliminating the need for proteases often used in RNA
detection, this advanced workflow preserves protein and RNA
integrity and conserves tissue morphology. With this advancement,
subcellular gene expression and multiomic changes can be easily
quantified and image and data analysis are further simplified.
"We are proud to achieve another milestone in our spatial
multiomics strategy with the development of a novel, protease-free
RNAscope workflow," said Kim
Kelderman, Bio-Techne's Chief Operating Officer. "We have
been impressed by the overwhelmingly positive response received
from customers who have tested this new workflow with our current
on-market RNAscope assays, and we look forward to offering this new
capability across our RNAscope portfolio this year."
Bio-Techne's ACD brand is a pioneer in spatial biology,
delivering industry-leading single-molecule sensitivity and
unrivaled specificity with its patented RNAscope ISH technology for
over 10 years. With over 9,500 peer reviewed publications and over
50,000 unique probes sold, RNAscope technology has enabled the
spatial detection of the widest range of RNA subtypes in the
industry from research to clinical applications.
Data will be showcased in a series of activities at the
Lunaphore Suite, Curacao 4 at the
Advances in Genome Biology and Technology (AGBT) 2024 General
Meeting in Orlando Florida on
February 5-8. Additional data
demonstrating technical advances in the codetection of RNA with
both proteins and protein-protein interactions using RNAscope will
be presented at AGBT by ACD scientist Ge-Ah
Kim, Ph.D. on Feb 7 at poster
#633 titled "Single-slide, in situ multiomic imaging of
mRNA, protein and protein-protein interactions in the tumor-immune
microenvironment of bladder cancer patients."
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With thousands of products in its portfolio,
Bio-Techne generated over $1.1
billion in net sales in fiscal 2023 and has approximately
3,100 employees worldwide. For more information on Bio-Techne and
its brands, please visit https://www.bio-techne.com or follow
the Company on social media at: Facebook, LinkedIn, Twitter or
YouTube.
Bio-Techne Investor Contact:
David Clair,
Vice President, Investor Relations and Corporate Development
612-656-4416
David.clair@bio-techne.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bio-technes-advanced-cell-diagnostics-acd-sets-new-standard-in-spatial-biology-with-protease-free-rnascope-multiomics-302046066.html
SOURCE Bio-Techne Corporation